Inactive Instrument

Epizyme, Inc.

Equities

EPZM

US29428V1044

Biotechnology & Medical Research

Epizyme, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021

May 06, 2021 at 09:56 am

Epizyme, Inc. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced total revenue was USD 7.631 million compared to USD 1.354 million a year ago. Operating loss was USD 64.337 million compared to USD 51.350 million a year ago. Net loss was USD 70.274 million compared to USD 50.937 million a year ago. Basic loss per share from continuing operations was USD 0.69 compared to USD 0.51 a year ago.

Latest news about Epizyme, Inc.

France's Ipsen Finalizes Purchase of US Biopharmaceutical Group Epizyme	15/08/22	MT
Epizyme Announces Management Changes	12/08/22	CI
Epizyme, Inc. Appoints Grant Bogle as Chief Executive Officer	12/08/22	CI
Epizyme, Inc.(NasdaqGS:EPZM) dropped from NASDAQ Composite Index	12/08/22	CI
Epizyme, Inc.(NasdaqGS:EPZM) dropped from S&P Global BMI Index	12/08/22	CI
Epizyme, Inc.(NasdaqGS:EPZM) dropped from S&P TMI Index	12/08/22	CI
Epizyme, Inc.(NasdaqGS:EPZM) dropped from NASDAQ Biotechnology Index	11/08/22	CI
Ipsen Biopharmaceuticals, Inc. completed the acquisition of Epizyme, Inc. from RP Management LLC and others.	10/08/22	CI
Earnings Flash (EPZM) EPIZYME Reports Q2 Revenue $27.5M	09/08/22	MT
Epizyme, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	09/08/22	CI
France's Ipsen Extends Tender Offer To Purchase US Biopharmaceutical Epizyme	05/08/22	MT
Hutchmed Starts Bridging Study Follicular Lymphoma Treatment in China	01/08/22	MT
North American Morning Briefing : Futures Waver -2-	29/06/22	DJ
Cowen Downgrades Epizyme to Market Perform From Outperform; Price Target is $1.50	28/06/22	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Monday	27/06/22	MT
Wall Street Set for Positive Open, Extending Gains on Easing Inflation Expectations	27/06/22	MT
Wedbush Cuts Epizyme to Neutral From Outperform, Price Target to $1.45 From $7, Citing Ipsen Offer	27/06/22	MT
Top Premarket Gainers	27/06/22	MT
Transcript : Epizyme, Inc., Ipsen S.A. - M&A Call	27/06/22
European shares hit two-week high as China eases COVID-19 curbs	27/06/22	RE
Epizyme Agrees to be Acquired by Ipsen for $247 Million	27/06/22	MT
France's Ipsen Launches Tender Offer to Purchase US Biopharmaceutical Epizyme	27/06/22	MT
Ipsen Biopharmaceuticals, Inc. entered into a definitive merger agreement to acquire Epizyme, Inc. from RP Management LLC and others for approximately $250 million.	26/06/22	CI
HC Wainwright Adjusts Epizyme's Price Target to $6 From $8, Reiterates Buy Rating	03/06/22	MT
Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R² Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting	02/06/22	CI

Chart Epizyme, Inc.

Duration

Period

More charts

Company Profile

Epizyme, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the treatment of people with cancer through the discovery, development, and commercialization of epigenetic medicines. The Company's lead product TAZVERIK (tazemetostat) is used for epithelioid sarcoma (ES), and follicular lymphoma (FL). Tazemetostat is an oral, selective small molecule inhibitor of the EZH2 histone methyltransferase (HMT), for the treatment of adult and pediatric patients aged 16 years and older with metastatic or locally advanced ES not eligible for complete resection. It is developing tazemetostat for lymphomas and B-cell malignancies, including B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), multiple myeloma and others. Its advanced product candidate, EZM0414, is an oral inhibitor of the SETD2 HMT. The Company is assessing the use of tazemetostat for immuno-oncology-sensitive tumors, such as small cell lung cancer, prostate cancer, and others.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.63%	103B
REGENERON PHARMACEUTICALS, INC.	+1.62%	95.28B
ARGENX SE	+1.46%	22.15B
BIONTECH SE	-16.67%	21.02B
GENMAB A/S	-8.58%	18.15B
WUXI APPTEC CO., LTD.	-38.74%	16.73B
BEIGENE, LTD.	-13.21%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+5.41%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.57%	12.17B

Bio Therapeutic Drugs